Matthew J Hobson
Private Equity Investor chez Catalio Capital Management LP
Profil
Matthew (Matt) Hobson, PhD is a Principal at Catalio Capital Management LP where he primarily covers investments in therapeutics and diagnostics for their venture and private credit strategies.
He currently represents Catalio on the board of Lassen Therapeutics and as a board observer of Anagenex, Iambic Therapeutics, Octant Therapeutics, and Pink Dx.
Matt joined Catalio at its founding in 2020.
Prior to joining Catalio, Matthew was a Postdoctoral Fellow at the Johns Hopkins School of Medicine where he also earned a PhD in biophysics and biophysical chemistry, applying a variety of structural, biochemical and protein engineering methods to study proteins involved in DNA replication and repair.
Matt also holds a B.S.
in chemistry and physics from Emory University.
Postes actifs de Matthew J Hobson
| Sociétés | Poste | Début |
|---|---|---|
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Private Equity Investor | 01/01/2020 |
Formation de Matthew J Hobson
| Emory University | Undergraduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Finance |